The brochure describes that vaccine is a special biological preparation administered to healthy individuals with the ability to stimulate immunity and protect the human body from infections and diseases. Conventional vaccine approaches such as inactivated pathogens and subunit vaccines and have prevented the spread of dozens of diseases. Along with the worldwide explosion of COVID-19 in 2020, a new vaccine platform, mRNA vaccine showed advantages of rapid development and scalable manufacture, which has been approved by FDA in early December, 2020 (BNT 162b2, Pfizer/BioNTech). Besides, mRNA vaccines can be more stable, at the same time, highly translatable through various modifications, allowing rapid cellular uptake and efficient expression. As mRNA is a noninfectious, non-integrating platform, there is no potential risk of infection or insertional mutagenesis which realizing higher safety of the mRNA vaccines.

In the past few years, lipid-based mRNA vaccine delivery has become one of the most appealing and commonly-used strategies. The lipid components could provide protection for mRNA and improve transfection efficiency. As an expert in lipid-based drug delivery, Creative Biolabs is dedicated to improve human health and has successfully established in both drug delivery platforms and pre-clinical vaccine platforms. We have absolute advantages in novel mRNA vaccine development.

Content

1. Background
2. Lipid-based mRNA Vaccines
3. Clinical Progress on Lipid-based mRNA Vaccines
4. Vaccine Formulation Development Service
5. Vaccine Analytics & Assessment Service